Wilmington, DE, United States of America

Rafael Herman

This inventor holds 1 USPTO granted patent. Top assignee: E.i. Dupont De Nemours and Company. Active years: 2003.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rafael Herman - Innovator in Scorpion Toxins

Introduction

Rafael Herman is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of biotechnology, particularly in the area of scorpion toxins. His innovative work has led to the development of a unique patent that showcases his expertise and creativity.

Latest Patents

Rafael Herman holds a patent related to scorpion toxins. This invention pertains to an isolated nucleic acid fragment encoding scorpion toxins that are K-channel modifiers. The patent also involves the construction of a chimeric gene encoding all or a substantial portion of the K-channel modifier, in sense or antisense orientation. The expression of this chimeric gene results in the production of altered levels of the K-channel modifier in a transformed host cell. He has 1 patent to his name.

Career Highlights

Rafael Herman is currently employed at E.I. du Pont de Nemours and Company, a leading company in the field of science and technology. His work at this organization has allowed him to further his research and development efforts in biotechnology.

Collaborations

Some of his notable coworkers include Albert Laurence Lu and James F. Wong. Their collaboration has contributed to the advancement of research in their respective fields.

Conclusion

Rafael Herman is a distinguished inventor whose work on scorpion toxins has made a significant impact in biotechnology. His innovative approach and collaboration with esteemed colleagues continue to drive advancements in this important area of research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…